P-378 Single institute experience of peri-operative FLOT chemotherapy

Patients with locally advanced gastric or gastroesophageal junction adenocarcinoma (LAGC) usually presents significant loss of weight and appetite affecting their overall performance status. FLOT regimen (5-Fluorouracil, Docetaxel oxaliplatin) has a proven role in perioperative management these cancers, however it its own share toxicities. In this retrospective single centre study we evaluate the compliance efficacy regime unselected non trial patients adequate status (PS), who underwent multi-modality treatment for LAGC chemotherapy surgery. Between March 2018 January 2022, 58 were diagnosed (histologically confirmed) planned FLOT. Baseline required consideration was ECOG PS 0 1. Patient demographics, chemotherapy, response assessment on pathological specimen progression free survival analysed. Prophylactic GCSF (Granulocyte Colony Stimulating Factor) used all patients. included study. The mean age 60.2years (Range 36-77 years) predominantly males (85%). 91% (53/58) completed 4 pre-operative only 72% (42/58) patient receiving standard dose. 58% (34/58) started post-operative 40% (23/58) able to complete 8 cycles 86% (50/58) surgery after 2 found have disease intra-operatively. 83% (40/48) had R0 resection. Mandard classification is at our evaluation tumour regression grading neo-adjuvant chemotherapy. 60.4% (29/48) TRG 4/5. didn’t either palliative consolidation RT without concurrent 14/48 total 22 developed recurrence. Mean Disease 19.7months as compared 21 months 12.4 didn’t. Until February 2023, 20 passed away due recurrence surgical complications. As seen reference FLOT4, population 60years majority males. Similarly preoperative though nearly 28% dose reduction Use prophylactic prevented neutropenia but 1 patient. Again, initial allocated adjuvant cycles. And half those (12/58) did Rate resection remain very similar original trial, showed poor 60%